Table 5. Pooled treatment related adverse events in breast cancer.

Study	Any-grade				Grade ≥3
	n	MR	95% CI		n	MR	95% CI
TNBC/anti-PD-L1 + nab-paclitaxel
IMpassion130	452	0.993	0.986–1.001		452	0.487	0.441–0.533
GP28328	–	–	–		33	0.727	0.575–0.879
Sub-total	–	–	–		485	0.596	0.361–0.830
TNBC + non-TNBC/anti-PD-L1
JAVELIN	168	0.685	0.614–0.755		168	0.137	0.085–0.189
TNBC/anti-PD-L1
PCD4989g	116	0.983	0.959–1.006		116	0.509	0.418–0.600
TNBC/anti-PD-1
KEYNOTE-012	32	0.563	0.391–0.734		32	0.156	0.030–0.282
KEYNOTE-086 cohort A	170	0.606	0.532–0.679		170	0.129	0.079–0.180
KEYNOTE-086 cohort B	84	0.631	0.528–0.734		84	0.095	0.032–0.158
Sub-total	286	0.609	0.552–0.665		286	0.120	0.082–0.157
Non-TNBC/anti-PD-1 + trastuzumab
PANACEA	–	–	–		58	0.500	0.371–0.629
Non-TNBC/an-PD-1
KEYNOTE-028	25	0.640	0.452–0.828		25	0.160	0.016–0.304

TNBC, triple-negative breast cancer; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; n, number of patients; MR, mean rate; CI, confidence interval.